Business
InMed Submits Clinical Trial Application to Evaluate INM-755 in Phase 1 Trial
InMed Submits Clinical Trial Application to Evaluate INM-755 in Phase 1 Trial Cana...
About this update from Infield Minerals Corp
[{"type":"text","content":"\n\n\n\nInMed Submits Clinical Trial Application to Evaluate INM-755 in Phase 1 Trial\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n\n\n\n\n\n\n\nCanada NewsWire\nVANCOUVER, Nov. 5, 2019\n\n\n\nVANCOUVER, Nov. 5, 2019 /CNW/ - InMed Pharmaceuticals Inc. (\"InMed\" or the \"Company\") (TSX: IN; OTCQX: IMLFF), today announced the filing of a Clinical Trial Application (\"CTA\") in the Netherlands to initiate a Phase 1 human clinical trial for INM-755 in healthy volunteers. \n\n \n \n\n \nINM-755 is a single-cannabinoid topical cream under development for the treatment of symptoms associated with epidermolysis bullosa (\"EB\"). It may also potentially address the underlying disease by enhancing skin integrity in a subset of EB Simplex patients. \nStudy #755-101-HV is a randomized, double-blind, vehicle-controlled, Phase 1 study designed to evaluate the local and systemic safety, tolerability, and pharmacokinetics of INM-755 cream applied daily on intact skin in healthy volunteers. Two strengths of INM-755 cream will be evaluated in 22 adult subjects over a 14-day treatment period.\n\"This filing follows the successful conclusion of an extensive preclinical development program that included 20 safety pharmacology and toxicology studies with treatment up to 28 days,\" says Alexandra Mancini, Senior Vice President of Clinical and Regulatory Affairs. \"We are very pleased with the preclinical data package, which further validates our scientific rationale and approach to treat EB, and look forward to starting the clinical phase of development and initiating subject screening and enrollment by year-end 2019.\" \n\"This is a significant milestone for the Company as we transition from a preclinical to a clinical stage organization,\" says Eric A. Adams, CEO. \"We have successfully demonstrated our ability to shepherd a novel compound through the tremendously complex process of preclinical testing and are well prepared to commence human clinical trials. With our extensive preclinical development package in hand, we are positioned to efficiently pursue additional indications for INM-7...